相似文献
1
Small lipidated anti-obesity compounds derived from neuromedin U.
Eur J Med Chem. 2015 Aug 28;101:616-26. doi: 10.1016/j.ejmech.2015.07.020. Epub 2015 Jul 14.
2
Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
J Med Chem. 2017 Jul 27;60(14):6089-6097. doi: 10.1021/acs.jmedchem.7b00330. Epub 2017 Jul 18.
3
A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
Bioorg Med Chem. 2017 Apr 15;25(8):2307-2312. doi: 10.1016/j.bmc.2017.02.023. Epub 2017 Feb 21.
4
Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models.
Pharmacol Res Perspect. 2018 Aug 23;6(5):e00425. doi: 10.1002/prp2.425. eCollection 2018 Oct.
5
Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake.
J Pept Sci. 2015 Feb;21(2):85-94. doi: 10.1002/psc.2727. Epub 2014 Dec 17.
6
PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration.
Peptides. 2017 Aug;94:99-105. doi: 10.1016/j.peptides.2017.04.001. Epub 2017 Apr 8.
7
Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Int J Obes (Lond). 2017 Dec;41(12):1790-1797. doi: 10.1038/ijo.2017.176. Epub 2017 Jul 31.
8
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
J Pept Sci. 2014 Jan;20(1):7-19. doi: 10.1002/psc.2582. Epub 2013 Nov 13.
9
Neuromedin U--a new target in obesity.
Expert Opin Ther Targets. 2005 Aug;9(4):875-7. doi: 10.1517/14728222.9.4.875.
10
Discovery of coumarin-dihydroquinazolinone analogs as niacin receptor 1 agonist with in-vivo anti-obesity efficacy.
Eur J Med Chem. 2018 May 25;152:208-222. doi: 10.1016/j.ejmech.2018.04.037. Epub 2018 Apr 21.
引用本文的文献
1
Suppressive Effects of Neuromedin U Receptor 2-Selective Peptide Agonists on Appetite and Prolactin Secretion in Mice.
ACS Med Chem Lett. 2024 Feb 14;15(3):376-380. doi: 10.1021/acsmedchemlett.3c00541. eCollection 2024 Mar 14.
2
Neuromedin U-deficient rats do not lose body weight or food intake.
Sci Rep. 2022 Oct 27;12(1):17472. doi: 10.1038/s41598-022-21764-6.
3
Insects as a New Complex Model in Hormonal Basis of Obesity.
Int J Mol Sci. 2021 Oct 14;22(20):11066. doi: 10.3390/ijms222011066.
4
Exploring Molecular Insights of Cereal Peptidic Antioxidants in Metabolic Syndrome Prevention.
Antioxidants (Basel). 2021 Mar 26;10(4):518. doi: 10.3390/antiox10040518.
5
Synthesis and Evaluation of Stabilized and Selective Neuromedin U-1 Receptor Agonists.
ACS Med Chem Lett. 2018 Apr 23;9(5):496-501. doi: 10.1021/acsmedchemlett.8b00105. eCollection 2018 May 10.
6
Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Int J Obes (Lond). 2017 Dec;41(12):1790-1797. doi: 10.1038/ijo.2017.176. Epub 2017 Jul 31.
本文引用的文献
1
Synthesis of mevalonate- and fluorinated mevalonate prodrugs and their in vitro human plasma stability.
Eur J Med Chem. 2015 Jan 27;90:448-61. doi: 10.1016/j.ejmech.2014.11.040. Epub 2014 Nov 22.
2
New insights into the autotaxin/LPA axis in cancer development and metastasis.
Exp Cell Res. 2015 May 1;333(2):183-189. doi: 10.1016/j.yexcr.2014.11.010. Epub 2014 Nov 25.
3
Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery.
Bioorg Med Chem Lett. 2014 Nov 15;24(22):5212-5. doi: 10.1016/j.bmcl.2014.09.072. Epub 2014 Oct 2.
4
A two-step strategy to enhance activity of low potency peptides.
PLoS One. 2014 Nov 12;9(11):e110502. doi: 10.1371/journal.pone.0110502. eCollection 2014.
5
Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone.
Blood. 2014 Nov 13;124(20):3141-50. doi: 10.1182/blood-2014-04-568683. Epub 2014 Oct 2.
6
Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2.
J Med Chem. 2014 Aug 14;57(15):6583-93. doi: 10.1021/jm500599s. Epub 2014 Jul 18.
7
Pancreatic safety of newer incretin-based therapies: are the "-tides" finally turning?
Diabetes. 2014 Jul;63(7):2219-21. doi: 10.2337/db14-0545.
8
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
Cancer Res. 2014 Jul 15;74(14):3821-33. doi: 10.1158/0008-5472.CAN-13-2053. Epub 2014 May 29.
9
Methods for quantifying lysophosphatidic acid in body fluids: a review.
Anal Biochem. 2014 May 15;453:38-43. doi: 10.1016/j.ab.2014.02.021. Epub 2014 Mar 5.
10
The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.
Diabetes. 2014 Jul;63(7):2486-97. doi: 10.2337/db13-1087. Epub 2014 Mar 7.
Zotero 插件